CFB and myeloid sarcoma: A proposed classification of reactive astrocytes sub-divided into neurotoxic A1 astrocytes vs. helpful A2 astrocytes was based on gene expression patterns including immunolabeling for C3+, MX1+, or CFB+ of A1 astrocytes in MS lesions (Liddelow et al., 2017).